Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.

ADAM10, as the sheddase of the low affinity IgE receptor (CD23), promotes IgE production and thus is a unique target for attenuating allergic disease. Herein, we describe that B cell levels of ADAM10, specifically, are increased in allergic patients and Th2 prone WT mouse strains (Balb/c and A/J). W...

Full description

Bibliographic Details
Main Authors: Lauren Folgosa Cooley, Rebecca K Martin, Hannah B Zellner, Anne-Marie Irani, Cora Uram-Tuculescu, Mohey Eldin El Shikh, Daniel H Conrad
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4416757?pdf=render
id doaj-6e92d27af04f4ca890a205078b791e6c
record_format Article
spelling doaj-6e92d27af04f4ca890a205078b791e6c2020-11-25T00:02:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012433110.1371/journal.pone.0124331Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.Lauren Folgosa CooleyRebecca K MartinHannah B ZellnerAnne-Marie IraniCora Uram-TuculescuMohey Eldin El ShikhDaniel H ConradADAM10, as the sheddase of the low affinity IgE receptor (CD23), promotes IgE production and thus is a unique target for attenuating allergic disease. Herein, we describe that B cell levels of ADAM10, specifically, are increased in allergic patients and Th2 prone WT mouse strains (Balb/c and A/J). While T cell help augments ADAM10 expression, Balb WT B cells exhibit increased ADAM10 in the naïve state and even more dramatically increased ADAM10 after anti-CD40/IL4 stimulation compared C57 (Th1 prone) WT B cells. Furthermore, ADAM17 and TNF are reduced in allergic patients and Th2 prone mouse strains (Balb/c and A/J) compared to Th1 prone controls. To further understand this regulation, ADAM17 and TNF were studied in C57Bl/6 and Balb/c mice deficient in ADAM10. C57-ADAM10B-/- were more adept at increasing ADAM17 levels and thus TNF cleavage resulting in excess follicular TNF levels and abnormal secondary lymphoid tissue architecture not noted in Balb-ADAM10B-/-. Moreover, the level of B cell ADAM10 as well as Th context is critical for determining IgE production potential. Using a murine house dust mite airway hypersensitivity model, we describe that high B cell ADAM10 level in a Th2 context (Balb/c WT) is optimal for disease induction including bronchoconstriction, goblet cell metaplasia, mucus, inflammatory cellular infiltration, and IgE production. Balb/c mice deficient in B cell ADAM10 have attenuated lung and airway symptoms compared to Balb WT and are actually most similar to C57 WT (Th1 prone). C57-ADAM10B-/- have even further reduced symptomology. Taken together, it is critical to consider both innate B cell levels of ADAM10 and ADAM17 as well as Th context when determining host susceptibility to allergic disease. High B cell ADAM10 and low ADAM17 levels would help diagnostically in predicting Th2 disease susceptibility; and, we provide support for the use ADAM10 inhibitors in treating Th2 disease.http://europepmc.org/articles/PMC4416757?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Lauren Folgosa Cooley
Rebecca K Martin
Hannah B Zellner
Anne-Marie Irani
Cora Uram-Tuculescu
Mohey Eldin El Shikh
Daniel H Conrad
spellingShingle Lauren Folgosa Cooley
Rebecca K Martin
Hannah B Zellner
Anne-Marie Irani
Cora Uram-Tuculescu
Mohey Eldin El Shikh
Daniel H Conrad
Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
PLoS ONE
author_facet Lauren Folgosa Cooley
Rebecca K Martin
Hannah B Zellner
Anne-Marie Irani
Cora Uram-Tuculescu
Mohey Eldin El Shikh
Daniel H Conrad
author_sort Lauren Folgosa Cooley
title Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
title_short Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
title_full Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
title_fullStr Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
title_full_unstemmed Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice.
title_sort increased b cell adam10 in allergic patients and th2 prone mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description ADAM10, as the sheddase of the low affinity IgE receptor (CD23), promotes IgE production and thus is a unique target for attenuating allergic disease. Herein, we describe that B cell levels of ADAM10, specifically, are increased in allergic patients and Th2 prone WT mouse strains (Balb/c and A/J). While T cell help augments ADAM10 expression, Balb WT B cells exhibit increased ADAM10 in the naïve state and even more dramatically increased ADAM10 after anti-CD40/IL4 stimulation compared C57 (Th1 prone) WT B cells. Furthermore, ADAM17 and TNF are reduced in allergic patients and Th2 prone mouse strains (Balb/c and A/J) compared to Th1 prone controls. To further understand this regulation, ADAM17 and TNF were studied in C57Bl/6 and Balb/c mice deficient in ADAM10. C57-ADAM10B-/- were more adept at increasing ADAM17 levels and thus TNF cleavage resulting in excess follicular TNF levels and abnormal secondary lymphoid tissue architecture not noted in Balb-ADAM10B-/-. Moreover, the level of B cell ADAM10 as well as Th context is critical for determining IgE production potential. Using a murine house dust mite airway hypersensitivity model, we describe that high B cell ADAM10 level in a Th2 context (Balb/c WT) is optimal for disease induction including bronchoconstriction, goblet cell metaplasia, mucus, inflammatory cellular infiltration, and IgE production. Balb/c mice deficient in B cell ADAM10 have attenuated lung and airway symptoms compared to Balb WT and are actually most similar to C57 WT (Th1 prone). C57-ADAM10B-/- have even further reduced symptomology. Taken together, it is critical to consider both innate B cell levels of ADAM10 and ADAM17 as well as Th context when determining host susceptibility to allergic disease. High B cell ADAM10 and low ADAM17 levels would help diagnostically in predicting Th2 disease susceptibility; and, we provide support for the use ADAM10 inhibitors in treating Th2 disease.
url http://europepmc.org/articles/PMC4416757?pdf=render
work_keys_str_mv AT laurenfolgosacooley increasedbcelladam10inallergicpatientsandth2pronemice
AT rebeccakmartin increasedbcelladam10inallergicpatientsandth2pronemice
AT hannahbzellner increasedbcelladam10inallergicpatientsandth2pronemice
AT annemarieirani increasedbcelladam10inallergicpatientsandth2pronemice
AT corauramtuculescu increasedbcelladam10inallergicpatientsandth2pronemice
AT moheyeldinelshikh increasedbcelladam10inallergicpatientsandth2pronemice
AT danielhconrad increasedbcelladam10inallergicpatientsandth2pronemice
_version_ 1725438218264903680